Oral Glycoprotein IIb/IIIa Inhibition With Orbofiban in Patients With Unstable Coronary Syndromes (OPUS-TIMI 16) Trial
- 11 July 2000
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Circulation
- Vol. 102 (2) , 149-156
- https://doi.org/10.1161/01.cir.102.2.149
Abstract
Background—Although intravenous glycoprotein IIb/IIIa inhibitors are beneficial in patients with acute coronary syndromes, prolonged oral IIb/IIIa inhibition might provide an additional reduction i...Keywords
This publication has 11 references indexed in Scilit:
- Long-Term Treatment with a Platelet Glycoprotein-Receptor Antagonist after Percutaneous Coronary RevascularizationNew England Journal of Medicine, 2000
- Increased platelet reactivity in patients given orbofiban after an acute coronary syndrome: an OPUS-TIMI 16 substudyThe American Journal of Cardiology, 2000
- Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trialThe Lancet, 2000
- Platelet activation in patients after an acute coronary syndrome: results from the TIMI-12 trialJournal of the American College of Cardiology, 1999
- Inhibition of Platelet Glycoprotein IIb/IIIa with Eptifibatide in Patients with Acute Coronary SyndromesNew England Journal of Medicine, 1998
- Inhibition of the Platelet Glycoprotein IIb/IIIa Receptor with Tirofiban in Unstable Angina and Non–Q-Wave Myocardial InfarctionNew England Journal of Medicine, 1998
- Role of GPIIb-IIIa in platelet-monocyte and platelet-neutrophil conjugate formation in whole bloodPlatelets, 1998
- Ligands “activate” integrin αIIbβ3 (platelet GPIIb-IIIa)Cell, 1991
- Designs for group sequential testsControlled Clinical Trials, 1984
- Prediction of Creatinine Clearance from Serum CreatinineNephron, 1976